Skip to the essay

Patient notes · November 2026

GLP-1 Journey

What the weeks feel like, from appetite to maintenance. No invented patient stories.

Note

Managing nausea and other GLP-1 side effects

Side effects are the reason the dose rises slowly. They are also the reason a calendar reminder is not a care plan. This note separates effects that are common in the trials from symptoms the labels tell you to treat as urgent. It does not rank drugs against each other. Wegovy’s label says, in the standard clinical-trial sentence, that adverse-reaction rates from one drug’s trials cannot be directly compared with rates from another drug’s trials. Zepbound’s label says the same thing. A “gentlest GLP-1” list is not something these documents support.

What showed up often in the Wegovy weight-reduction trials

In adults treated with Wegovy injection 2.4 mg in the weight-reduction program summarized on the label, 6.8 percent stopped the drug because of adverse reactions, compared with 3.2 percent on placebo. The most common reasons for stopping were nausea, vomiting, and diarrhea. Gastrointestinal adverse reactions were reported by 73 percent of people on Wegovy injection and 47 percent on placebo. Severe gastrointestinal reactions were reported in 4.1 percent versus 0.9 percent. The most frequent were nausea (44 percent versus 16 percent), vomiting (25 percent versus 6 percent), and diarrhea (30 percent versus 16 percent). The label says these were most often reported during dose escalation and were usually mild or moderate, which can be true of the average and still be miserable for a person who cannot work a shift.

Other effects listed as occurring at a higher rate include dyspepsia, abdominal pain and distension, burping, flatulence, reflux, and, in the broader highlights, headache, fatigue, dizziness, and hair loss. Gallstones were reported by 1.6 percent of adults on Wegovy injection versus 0.7 percent on placebo in the weight-reduction trials, and cholecystitis by 0.6 percent versus 0.2 percent. Heart rate rose by a mean of about 1 to 4 beats per minute in adult trials. Those numbers are a reason to mention palpitations and right-upper-abdominal pain, not a reason to diagnose yourself.

Zepbound’s highlights list, as reactions reported in at least 5 percent of treated patients, nausea, diarrhea, vomiting, constipation, abdominal pain, dyspepsia, injection-site reactions, fatigue, hypersensitivity, burping, hair loss, and reflux. In the pool of placebo-controlled weight-reduction trials, 4.8 percent, 6.3 percent, and 6.7 percent of patients on 5 mg, 10 mg, and 15 mg permanently discontinued because of adverse reactions, versus 3.4 percent on placebo, mostly early and mostly gastrointestinal. Saxenda’s label has its own discontinuation rule for adults: evaluate weight about 16 weeks after starting, and stop the drug if the person has not lost at least 4 percent of baseline weight, because meaningful loss is then unlikely. That 16-week rule is specific to Saxenda. Do not apply it to Wegovy or Zepbound on your own.

What you can change without changing the drug

Smaller meals, less fried food, and slower eating are the first adjustments clinicians and the JAMA Internal Medicine patient page describe for nausea. That page also suggests staying upright after meals when reflux is the issue, and using both soluble and insoluble fiber plus fluid for constipation. NIDDK’s eating pattern, vegetables, fruit, whole grains, and beans, is the food version of that fiber advice. Ginger tea is a home comfort the JAMA page mentions. It is not a labeled treatment.

Hydration is the piece people skip when they feel full of water. The Wegovy and Zepbound labels both warn that diarrhea, nausea, and vomiting can cause dehydration and acute kidney injury, sometimes serious enough to need dialysis in postmarketing reports of semaglutide. The instruction to patients is to drink fluids and to report vomiting or diarrhea that does not go away. If you cannot keep fluids down, that report should be the same day, not at the next monthly refill.

Constipation that lasts is a reason to look at fiber, fluid, movement, and any constipating medicines you already take, such as some pain medicines and iron. It is also a reason to ask before you use daily laxatives. A bowel obstruction is not ordinary constipation. Worsening pain, vomiting, and a belly that is not passing gas need urgent care. This note cannot tell those apart through a screen.

Injection-site redness is listed with Zepbound. Rotating sites, as the instructions for use say, is the basic prevention. Spreading redness, fever, or a lump that worsens is a clinician question. Do not inject through irritated skin to “use up the pen.”

Symptoms that should stop the casual approach

Pancreatitis. Both labels say acute pancreatitis, including fatal and hemorrhagic forms, has been seen with GLP-1 receptor agonists, and they tell patients to stop the drug and get care for severe abdominal pain that may radiate to the back, with or without vomiting. Do not take the next dose while you wait to see if the pain is “just nausea.”

Gallbladder disease. Pain in the upper abdomen, especially on the right, with fever or jaundice, needs evaluation. Weight loss itself is associated with gallstones. The drug labels report the events. Surgery is sometimes required. A heating pad is not the workup.

Allergy. Serious hypersensitivity, including anaphylaxis and angioedema, has been reported. Swelling of the face or throat, wheezing, or a widespread rash is emergency care. A prior serious reaction to semaglutide is a contraindication to Wegovy. That includes other semaglutide brands, not only the pen you started this month.

Low blood sugar. If you use insulin or a sulfonylurea, the labels warn that hypoglycemia, including severe hypoglycemia, is more likely. Shakiness, sweating, and confusion in that setting are a glucose problem until proven otherwise. The prescriber may already have planned a dose reduction of the other drug. If that plan was never made, call before you escalate the GLP-1 dose. The medicine reference which GLP-1 medicines keeps the diabetes products and the weight-management products from being treated as the same pen.

Mood. Report new or worsening depression or thoughts of self-harm to a clinician promptly. This note does not claim a proven rate from a single table, and it does not dismiss the report. Emergency services are the right call if you might act on those thoughts.

Pregnancy. Stop and call. Wegovy’s label says the drug may cause fetal harm and should be discontinued when pregnancy is recognized for the weight and cardiovascular uses. Do not wait for the next scheduled titration.

How this fits the rest of the notebook

Hair loss is worth a calmer paragraph because it scares people into stopping or into buying a supplement. The labels list it among common reactions. It often appears after weight has already been falling, which is also when people notice more hair in the shower for other reasons, including rapid weight loss itself and low protein intake. Mention it at a visit. Mention how little you have been eating. Do not start a handful of unreviewed powders because a listing included the word hair. A clinician can look for iron or thyroid issues when the story suggests them. The drug label does not appoint a shampoo as treatment.

The first twelve weeks are when escalation crowds these effects together. What to eat is the food version of the nausea and constipation advice. If side effects are tolerable and the scale has simply stopped moving for a while, that is a different problem, covered in plateaus. Do not raise your own dose to chase a plateau. The labels leave the next step with the prescriber, who is also the person who can delay it.

Sources we used

  1. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
  2. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217806s041lbl.pdf
  3. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/206321s024lbl.pdf
  4. https://utswmed.org/medblog/glp1-frequently-asked-questions/
  5. https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2836527
  6. https://www.niddk.nih.gov/health-information/weight-management/adult-overweight-obesity/eating-physical-activity
  7. https://glp1meds.org/monographs/which-glp-1-medicines